Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab.
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
J
J
Tkaczuk
E
E
Milford
C
C
Yu
S
S
Baksh
C
C
Carpenter
S
S
Burakoff
D
D
McKay
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D002460:Cell Line; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D000077561:Daclizumab